| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-56 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 |
| filingDate |
2002-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2004-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20040022244-A |
| titleOfInvention |
Hybrid interferon/interferon tau proteins, compositions and method of use |
| abstract |
The present invention relates to a hybrid interferon hybrid protein in which the C-terminal region of the interferon-α protein is formed of an interferon-α protein substituted with the C-terminal region of interferon-τ. Nucleic acid sequences encoding interferon hybrid proteins, expression vectors containing such sequences, therapeutic use of interferon hybrid proteins have also been described. Therapeutic use includes antiviral, anti cell proliferation, anti inflammatory use. One advantage of the interferon hybrid polypeptides of the present invention is the low cytotoxic side effects when used to treat cells. |
| priorityDate |
2001-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |